These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37793875)

  • 61. Clinical roundtable monograph. Overall survival and maintenance of MDS patients.
    Silverman LR
    Clin Adv Hematol Oncol; 2009 Jul; 7(7):S3-5. PubMed ID: 19708287
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Myelodysplastic syndromes: Contemporary review and how we treat.
    Gangat N; Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Azacitidine for the treatment of myelodysplastic syndrome.
    Cataldo VD; Cortes J; Quintás-Cardama A
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):875-84. PubMed ID: 19589026
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.
    Keating GM
    Drugs; 2012 May; 72(8):1111-36. PubMed ID: 22571445
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions.
    Short NJ; Kantarjian H
    Am J Hematol; 2022 Dec; 97(12):1616-1626. PubMed ID: 35871436
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
    Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
    Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
    Cluzeau T; Mounier N; Karsenti JM; Richez V; Legros L; Gastaud L; Garnier G; Re D; Montagne N; Gutnecht J; Gabriel Fuzibet J; Auberger P; Raynaud S; Cassuto JP
    Am J Hematol; 2013 Sep; 88(9):780-3. PubMed ID: 23757315
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Current status and trends in the diagnostics of AML and MDS.
    Shumilov E; Flach J; Kohlmann A; Banz Y; Bonadies N; Fiedler M; Pabst T; Bacher U
    Blood Rev; 2018 Nov; 32(6):508-519. PubMed ID: 29728319
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Current treatment strategies for myelodysplastic syndromes].
    Suzuki T
    Rinsho Ketsueki; 2015 Oct; 56(10):1985-95. PubMed ID: 26458437
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

  • 73. How do molecular aberrations guide therapy in MDS?
    Bejar R
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101324. PubMed ID: 34865696
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.
    Yanada M; Mizuno S; Yamasaki S; Harada K; Konuma T; Tamaki H; Shingai N; Uchida N; Ozawa Y; Tanaka M; Onizuka M; Sawa M; Nakamae H; Shiratori S; Matsuoka KI; Eto T; Kawakita T; Maruyama Y; Ichinohe T; Kanda Y; Atsuta Y; Aoki J; Yano S
    Leuk Lymphoma; 2021 Dec; 62(14):3411-3419. PubMed ID: 34348554
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
    Feld J; Belasen A; Navada SC
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH; Komrokji RS; List AF
    Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
    Ishikawa T
    Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
    Maggioni G; Della Porta MG
    Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
    Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
    Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
    Zeidan AM; Lee JW; Prebet T; Greenberg P; Sun Z; Juckett M; Smith MR; Paietta E; Gabrilove J; Erba HP; Katterling RP; Tallman MS; Gore SD
    Br J Haematol; 2014 Oct; 167(1):62-8. PubMed ID: 24995683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.